Hemoglobin (Hgb) greater than . g/dL (may have packed red blood cell [PRBC] transfusion)
Hemoglobin >  g/dL (prior red blood cell [RBC] transfusion allowed); patients may be transfused to achieve this value
Inability to receive HCT due to alloimmunization, defined as the inability to receive packed red blood cell (pRBC) transfusion therapy.
Hemoglobin <  g/dL (< . mmol/L; previous red blood cell [RBC] transfusion is permitted).
Have a hemoglobin ?. g/dL without red blood cell transfusion for ? month.
Hemoglobin >=  g/dL (with or without packed red blood cell [PRBC] transfusion) and documented within  days prior to registration and within  days prior to the start of treatment
Hemoglobin >. mg/dL without red blood cell transfusion ?  days prior to CD
Hemoglobin >= . g/dL (with or without red blood cell [RBC] transfusion)
Hemoglobin <  g/dL (< . mmol/L; previous red blood cell transfusion is permitted)
Subjects should not have packed red blood cells (PRBC) or platelet transfusion within  days of the screening
Hemoglobin: >= . gm/dl (may transfuse peripheral red blood cells [PRBCs])
Hemoglobin <  g/dL (< . mmol/L; previous red blood cell [RBC] transfusion is permitted)
Hemoglobin ?. g/dL (must be > weeks post-red blood cell transfusion)
Within  days prior to administration of study treatment: Hemoglobin >=  g/dL with no pack red blood cell transfusion in the past  days
Within two weeks prior to enrollment: Hemoglobin >=  gm/dL and >  days since last red blood cell transfusion
Hemoglobin >= . g/dL (may receive packed red blood cell [prbc] transfusion)
Within  days before the first dose of study drug: hemoglobin >  g/dL (prior red blood cell [RBC] transfusion allowed); patients may be transfused to achieve this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed
Hemoglobin ?  g/dL (red blood cell [RBC] transfusion is allowed)
Hemoglobin (Hgb) >=  g/dL with or without packed red blood cells (pRBC) transfusion
Patients may be transfused with packed red blood cells (PRBCs) up to  days prior to when enrollment labs are drawn to achieve Hgb >= . mg/dL
Platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and treatment to achieve a target plt >= ,/uL and hemoglobin of >= . g/dl, provided that patients have not received growth factors for at least  days prior to entering trial
Hemoglobin >= . g/dL\r\n* Patients may have a transfusion of red blood cells to meet the hemoglobin requirement
PART  GROUP  INCLUSION CRITERIA: Hemoglobin (Hgb) >=  g/dL (may receive red blood cell [RBC] transfusion)
UROTHELIAL CARCINOMA EXPANSION COHORT: Hemoglobin >=  g/dL in the absence of packed red blood cells transfusion  days prior to dosing OR >  g/dL, if the value is constant across  readings within  weeks in the absence of packed red blood cells transfusion  days prior to dosing
Patients must have hemoglobin >= . g/dl; platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and during treatment to achieve a target hemoglobin of >= ./ul provided that patients have not received growth factors for at least  days prior to entering trial
Hemoglobin >= . mg/dL without red blood cell transfusion =<  days prior to CD
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHemoglobin (Hgb) >=  g/dL in the absence of packed red blood cell transfusion  days prior to dosing OR Hgb -. g/dL and the value is constant across  readings within  weeks, in the absence of packed red blood cell transfusion  days prior to dosing
PHASE II COLORECTAL CANCER COHORT  (MEDI+C ONLY):\r\nHemoglobin (Hgb) >=  g/dL in the absence of packed red blood cell transfusion  days prior to dosing
Hemoglobin >=  g/dL (packed red blood cell [pRBC] transfusion +/- erythropoiesis-stimulating agents [ESA] are allowed) (must be within  days of MLA)
Hemoglobin >=  g/dL (packed red blood cell [PRBC] transfusions permitted)
Hemoglobin (Hgb) greater than . g/dL (may have packed red blood cell [PRBC] transfusion)
Hemoglobin (>=) . gram per deciliter (g/dL) ([>=]  millimole per liter [mmol/L]; prior red blood cell [RBC] transfusion is permitted)
Part : hemoglobin level of ?  g/dL within  weeks of enrollment\r\n* Packed red blood cell (PRBC) transfusions will be allowed to patients with hemoglobin < g/dl
Hemoglobin < . g/dL (red blood cell transfusion and erythropoietin may be used to reach at least . g/dL, but must have been administered at least  weeks prior to the first dose of study drug.
Hemoglobin >=  g/dL (packed red blood cells [PRBC] transfusions permitted)
Hemoglobin >=  g/dL, without ongoing chronic blood transfusion or colony stimulating factor support to maintain normal levels; principal investigator approval is required; (limited red blood cell [RBC] transfusion is allowed for an acute change in hemoglobin)
Hemoglobin >= . g/dL or >= . mmol/L, specimens must be collected within  days prior to the start of study treatment\r\n* Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last  weeks
Hemoglobin >=  g/dl (may be after transfusion of packed red blood cells or use of erythropoiesis stimulating agents)
Absence of a regular red blood cell transfusion requirement
Hemoglobin >= . gm/dL (may receive packed red blood cell [PRBC] transfusions)
Patients must not have received a transfusion (platelets or red blood cells) within  weeks of the first dose of study treatment.
Platelet or packed red blood cell transfusion within  days of pre-treatment evaluation
Patients who have received hematopoietic growth factor support within  days of day  of ibrutinib; patients who are Jehovahs witnesses may be given an erythropoiesis-stimulating agent before and during the trial in lieu of red blood cell transfusions but anemia and/or red blood cell (RBC) transfusion dependence cannot be used for response assessment in these patients
Hemoglobin (Hgb) >= . g/dL (no red blood cell [RBC] transfusion within past  days)
Hemoglobin (Hgb) >=  g/dL and no red blood cell (RBC) transfusion within the past  days prior to study registration
Hemoglobin < g/dL (<. mmol/L; prior red blood cell [RBC] transfusion is permitted)
Hemoglobin >=  (packed red blood cells [pRBC] transfusion +/- erythropoiesis-stimulating agents [ESA] are allowed) (must be within  days of MLA)
Hematocrit =< % or hemoglobin =<  g/dL (but may have red blood cell [RBC] transfusion)
Hemoglobin >=  g/dL (may have received packed red blood cell transfusion)
Hemoglobin >=  g/dl (may transfuse packed red blood cells [PRBC] to meet parameter)
Hemoglobin >=  g/dL; subjects may not have had a red blood cell (RBC) transfusion within  days of screening assessment
Hemoglobin >= . mg/dL without red blood cell transfusion =<  days prior to cycle  day  of therapy
Packed red blood cell or platelet transfusion within  days of screening laboratory tests.
Hemoglobin >=  g/dl without packed red blood cell dependency, unless due to bone marrow involvement with lymphoma
Hemoglobin ? . g/dL and not requiring >  unit red blood cell transfusion per month; subjects receiving therapeutic erythropoietin preparations in accordance with the FDA product label are eligible to enroll;
Hemoglobin <  g/dL (< . mmol/L; previous red blood cell transfusion is permitted)
Red blood cell transfusion within  weeks prior to anticipated start of study treatment.
Anemia, Hemoglobin (Hgb) ? . g/dL or ?  units of Red Blood Cells (RBCs) within  days
Has received a transfusion (platelets or red blood cells) within  weeks before the first dose of niraparib
Has received a transfusion (platelets or red blood cells) within  weeks of the first dose of niraparib
Hemoglobin ?  g/dL without red blood cell transfusion within  hours of screening.
Hemoglobin (Hgb) >=  g/dL and no red blood cell (RBC) transfusion within the past  days prior to study registration
Hemoglobin >= . gm/dL (may receive packed red blood cell [pRBC] transfusions)